Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,473 total articles
Olympic Steel's strategic move has changed the competitive and earnings dynamics for Ryerson (RYI). The market has yet to fully price in the odds of meaningful margin improvement and cash-flow stabilization. This trade idea outlines an actionable long with a clear entry at $18.50, a stop at $14.75, and a target of $26.00 over a mid-term horizon (45…
Loblaw Companies looks priced for perfection while secular and cyclical pressures are building. We lay out a mid-term short trade with a clear entry at $45.00, stop at $52.50 and a first target at $38.00, explaining the fundamental drivers, catalysts and the scenarios that would change our mind.
Backblaze has moved from pure backup provider to a low-cost data lake for AI workloads. Recent results and a $335M CoreWeave partnership suggest the legacy "backup drag" is easing. This is a mid-term swing trade: enter at $15.50, target $22.00, stop $13.50, horizon 45 trading days, risk medium.
Applied Optoelectronics (AAOI) has been a poster child for the AI-driven optics rally. The stock's run and a fresh $600M ATM offering on 08/24/2026 suggest the market is pricing near-perfect execution and persistent, margin-rich growth. Fundamentals tell a different story: negative free cash flow, a stretched price-to-sales multiple, and repeated e…
Gen Digital reported strong Q3 FY26 results, raised guidance and continues to convert subscription cash flow into shareholder returns. If a distribution tie-in with MoneyLion (or similar fintech partners) materializes for its Trust-Based Solutions, Gen could unlock a new, high-margin channel at a valuation that looks reasonable versus cash flow. Th…
Dianthus Therapeutics (DNTH) is a clinical-stage biotech that just experienced a sector-driven sell-off in complement/C1s names. With Phase 3 momentum, sizable recent financings and a concentrated short interest, this pullback presents a tactical long setup. Entry $108.00, stop $95.00, target $150.00 over a mid-term (45 trading days) horizon.
LyondellBasell (LYB) looks healthier than it did a year ago: cash generation is positive, leverage is manageable, and commodity fundamentals (ethylene/resins) still favor producers. The company is smaller and less generous on payout, but that conservatism improves balance-sheet optionality. We upgrade to a buy for a mid-term swing trade targeting c…
Amazon's cloud business is accelerating and the market is finally giving the stock room to rerate. AWS growth, spotty retail cycles notwithstanding, plus a massive $220 billion capex push into AI infrastructure, supports a rating upgrade to long. Trade plan: enter at $264.00, stop $250.00, target $320.00 over the next 180 trading days.
Marti Technologies (MRT) is a tech-enabled urban mobility operator in Turkiye trading at ~$180M market cap. Price action and moving averages are turning constructive, short interest has pulled back, and the stock sits well above its moving-average structure. For disciplined risk-takers, a long with a defined stop captures an asymmetric upside towar…
Embecta is a beaten-up manufacturer of insulin delivery supplies trading at a fraction of prior valuation. With positive free cash flow, a low P/E, and clear near-term operational catalysts, the stock is an asymmetric risk-reward for disciplined bottom-fishing. This trade plan lays out entry, stop, target, horizon and key risks.
CME Group is trading near $279 after a period of sideways action, but several internal growth drivers and a juicy 4% yield argue for a long trade. The business is a high-margin, cash-generative marketplace with rising activity across interest rates, FX and clearing. Valuation is full on some metrics, but earnings power and a healthy dividend provid…
Fannie Mae is trading at $6.27 with a $7.26B market cap after reporting $3.7B in Q1 2026 net income. With ongoing portfolio cleanup, credit-scoring modernization, and public commentary around an IPO roadmap, we propose a mid-term (45 trading days) long trade that captures upside as markets price in progress toward privatization.
Telix has moved from a development-stage story into a commercial-scale radiopharmaceutical company. Q2 revenue of $247M and Precision Medicine strength ($202M) underpin a thesis that execution can unlock meaningful upside. This trade idea is a disciplined long that banks on continued commercial momentum, ProstACT Phase 3 progress, and regulatory al…
ATRenew's Q2 showed the same operational pulse that drove its earlier rebound: improving margins, active supply-side throughput and expanding distribution. With a $899M market cap, a PE of 14.5 and a 2.4% cash dividend yield, the setup offers asymmetric upside into a mid-term re-rating if momentum persists. Trade plan: enter $4.10, stop $3.60, targ…
Copart (CPRT) has been sold off amid a CEO transition, an earnings miss and activism/litigation headlines. Fundamentals remain solid: strong margins, conservative balance sheet and attractive cash generation. Technical momentum and a manageable short-interest profile set up a mid-term swing trade: buy into the dip with a clear stop and an upside ta…
GE Vernova sits at the center of a structural power-equipment shortage driven by AI data center buildouts and utility underinvestment. With a $176B backlog, sold-out gas turbine capacity through 2030, and healthy free cash flow, the company looks primed to convert supply constraints into higher margins. This trade idea lays out an actionable mid-te…
Rocket Lab offers a unique combination of public liquidity, meaningful backlog, recent large defense wins and an imminent technology catalyst in Neutron's first flight. At a current market cap of roughly $40.8B and trading near $68.37, the stock is richly valued on sales but offers a clearer, tradable path to upside for public-market investors comp…
Western Digital (WDC) just sold off into a constructive area after a strong earnings print and bullish guidance. The company trades with healthy cash flow, low leverage and high ROE while hyperscaler demand for storage remains the dominant fundamental driver. This trade idea outlines an entry at $440.00, a stop at $385.00, and a target at $560.00 o…
AbbVie ($264.56) is trading near its 52-week high while fundamentals and technicals point to further upside. With free cash flow of $18.21B, a 2.6% yield, accelerating growth from Skyrizi and Rinvoq, and bullish momentum signals, a controlled long with a $255 stop and $285 target offers an asymmetric risk-reward over the next 45 trading days.
Arlo's transition to a subscription-first model is driving meaningful revenue mix improvement and predictable cash flow. With subscriptions reported at >60% of revenue in the last reported quarter and free cash flow positive, the stock at ~$13 offers a structured long trade that targets the prior regime highs while keeping a clear stop beneath the …
Coeur Mining (CDE) has moved out of bargain territory as the stock re-rates with higher cash flows and improving margins. The business fundamentals - diversified North American asset base, low leverage, and >$1.1B in free cash flow - support more upside. This is a tactical long with an entry at $21.00, stop at $18.50 and primary target $30.00 over …
<p>Adyen has the structural ingredients to compound at ~20% annually over multiple years: a direct-to-merchant model, expanding product set, and durable network effects. After a protracted multiple compression, the risk/reward now favors accumulation for a long-term position. This trade plan outlines an entry, stop and target across defined horizon…
Kaspi.kz (KSPI) is buying Rabobank's Turkish arm, a move that could accelerate deposit funding, merchant density and cross-sell in a large, underpenetrated market. The stock trades at a reasonable multiple today, offers a 3.3% yield and carries a clear catalyst path. I lay out an entry at $106.15, a protective stop at $95.00 and a long-term target …
Caleres (CAL) just earned a practical upgrade. Recent Q4 beats and a 2026 guide that calls for a return to profitability, combined with low multiples (EV/EBITDA ~7.5, P/S ~0.16, P/B ~0.75) and an improving e-commerce mix, make a measured long position attractive over the next 45 trading days. Trade plan below with entry, stop, targets and clear ris…
Nurix's $700M upfront partnership with Roche materially changes the company's capital profile and commercial path for bexobrutideg, its BTK degrader for B‑cell malignancies. The deal de-risks follow-on financing and shifts the valuation discussion from balance-sheet risk to execution and clinical readouts. I outline an actionable long trade with en…
